Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02763072
Other study ID # C-16-EV09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date June 26, 2017

Study information

Verified date May 2023
Source Cutera Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of two laser systems for improvement of lentigines on the hands.


Description:

The purpose of this study is to evaluate the effectiveness and safety in a clinic setting of two laser systems for the treatment of lentigines (liver spots, age spots, or dark sun spots) on the hands.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date June 26, 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 90 Years
Eligibility Inclusion Criteria: 1. Female or Male, 30-90 years of age (inclusive). 2. Fitzpatrick Skin Type I - III. 3. Desires non-invasive and non-ablative treatment of lentigines on the hand(s). 4. Have 4 or more lentigines on the hand(s). 5. Subject must be able to read, understand and sign the Informed Consent Form. 6. Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. 7. Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period. 8. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes. 9. Agree to not undergo any other procedure(s) for treatment of lentigines during the study, including but not limited to chemical peel, laser and light based device treatment, and home-use device treatment. 10. Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler to the treatment area during the study. Exclusion Criteria: 1. Participation in a clinical trial of another device or drug in the target area within 6 months prior to enrollment or during the study. 2. Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser or light-based procedures or surgery. 3. Systemic use of retinoid, such as isotretinoin, within 6 months of study participation. 4. Use of topical medications on the hands, such as antibiotics, benzoyl peroxide, retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing dihydroxyacetone or alpha-hydroxy with concentration > 8%, within 1 month of participation. 5. History of malignant tumors in the target area. 6. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles. 7. Pregnant. 8. Having an infection, dermatitis, or a rash in the treatment area. 9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing. 10. Any use of medication that is known to increase sensitivity to light according to investigator's discretion. 11. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. 12. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. 13. Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus. 14. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. 15. In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systematic therapy that could interfere with this research study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Enlighten Laser

Excel V Laser


Locations

Country Name City State
United States DuPage Medical Group Naperville Illinois

Sponsors (1)

Lead Sponsor Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers. 4 weeks post-final treatment
Secondary Physician's Global Assessment Score of the Overall Appearance of the Hands Degree of improvement in the overall appearance of the hands as assessed by blinded reviewers using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change Higher scores indicate better outcomes 4 weeks post final treatment
Secondary Physician's Global Assessment Score of Skin Texture of the Hands Degree of improvement in the Skin Texture of the hands as assessed using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change. Higher scores indicate better outcomes 4 weeks post final treatment
Secondary Subject Satisfaction Subject-completed questionnaire to rate their level of satisfaction with the laser treatment outcome 4 weeks post final treatment
See also
  Status Clinical Trial Phase
Completed NCT02492373 - Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser N/A
Completed NCT02385994 - A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin N/A